RA-260 (ARA-290 high dose)Tissue RepairSafety Rating 6/10

Primary research areaNeuropathic pain

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeResearch compound. Dosing parallels ARA-290 protocols — 4–8 mg/day SC.
AdministrationVaries
Safety6/10 · Not FDA-approved
NCAA D1Banned

Price Comparison

Compare vendors

No vendor pricing available for this peptide yet.

Overview

About RA-260

Mechanism of action

Research peptide listed alongside ARA-290 class; likely refers to a higher-dose formulation or related non-erythropoietic EPO-derived peptide; activates innate repair receptor (IRR); anti-inflammatory and tissue repair.

Safety profile

Limited specific data for RA-260 formulation. Assumed similar to ARA-290: injection site reactions, generally well-tolerated. · High-dose ARA-290 variant; limited data; parent compound (ARA-290) well-tolerated in trials

📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on RA-260

Failed to fetch